

Published in final edited form as:

Am J Prev Med. 2014 August; 47(2): 203–211. doi:10.1016/j.amepre.2014.04.007.

# Influenza Vaccination Among Persons with Work-Related Asthma

#### Jacek M. Mazurek, MD,

Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Morgantown, West Virginia

### Gretchen E. White, MPH,

Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Morgantown, West Virginia

#### Jeanne E. Moorman, MS, and

National Center for Environmental Health, CDC, Atlanta, Georgia

## Eileen Storey, MD

Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Morgantown, West Virginia

## **Abstract**

**Background**—Seasonal influenza vaccination is recommended for all asthma patients. Persons with work-related asthma may have more severe disease than those with non–work-related asthma and may particularly benefit from receiving influenza vaccination.

**Purpose**—To determine if influenza vaccination coverage differs among individuals aged 18–64 years with work-related and non–work-related asthma.

**Methods**—Data from the 2006–2009 Behavioral Risk Factor Surveillance System Asthma Call-Back Survey collected in 38 states and the District of Columbia were analyzed in 2013. Multivariable logistic regression and predictive marginal analyses were conducted to identify factors independently associated with influenza vaccination among respondents aged 18–64 years with work-related asthma.

**Results**—Among adults aged 18–64 years with current asthma, an estimated 42.7% received influenza vaccination in the past 12 months. Although influenza vaccination coverage was significantly higher among adults with work-related asthma than those with non–work-related asthma (48.5% vs 42.8%), this association became non-significant after adjustment for demographic and clinical characteristics (prevalence ratio=1.08, 95% CI=0.99, 1.20). Among individuals with work-related asthma, receiving the influenza vaccine was associated with being

Address correspondence to: Jacek M. Mazurek, MD, Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Surveillance Branch, Mailstop HG 900.2, 1095 Willow-dale Road, Morgantown WV 26505. imazurek1@cdc.gov.

The findings and conclusions in this report are those of authors and do not necessarily represent the views of the CDC. No financial disclosures were reported by the authors of this paper.

50–64 years old, being unemployed in the prior year, and seeking urgent treatment for worsening asthma symptoms.

**Conclusions**—Among persons with work-related and non–work-related asthma, less than half received influenza vaccination in the prior year, both below the Healthy People 2010 target of 60%. These results suggest the need for strengthening current vaccination interventions to meet the updated Healthy People 2020 objective of achieving at least 70% influenza vaccination coverage.

## Introduction

In 2010, an estimated 18.7 (8.2%) million U.S. adults had asthma. Asthma was the most frequently reported comorbid condition among patients hospitalized with 2009 H1N1 influenza. Annual influenza vaccination is the most effective method for preventing infection with influenza virus, preventing infection-associated complications, and reducing work absenteeism. In 2006–2009, annual influenza vaccination was recommended for adults with asthma. Annual influenza vaccination was recommended for

Work-related asthma (WRA) is asthma that is caused or exacerbated by work-related factors. <sup>12</sup> We previously reported that among adults with current asthma, 9% were diagnosed with WRA and an additional 38% describe their asthma as caused or worsened by workplace exposures (possible WRA). <sup>13</sup> Persons with WRA have lower SES and may have more severe disease than those with non-WRA. <sup>13–15</sup> Therefore, persons with WRA may be at higher risk for severe asthma exacerbation associated with influenza virus infection than those with non-WRA. <sup>16,17</sup>

Although previous studies have examined influenza vaccination coverage in persons with asthma, no information is available for those with WRA. <sup>18–20</sup> Data from the 2006–2009 Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-Back Survey (ACBS) were analyzed to determine influenza vaccination coverage differences among individuals with WRA and non-WRA.

# **Methods**

A detailed description of the survey methods is available else-where. <sup>21–23</sup> Classification of asthma, asthma-related healthcare utilization, asthma outcomes, and asthma control were based on previously used definitions. <sup>13–15</sup> Participants with current asthma were classified as having WRA (diagnosed), possible WRA, and non-WRA (referent group). Influenza vaccine recipients were those who received an influenza vaccine injection or nasal spray. Number of physician contacts for asthma in the past 12 months was calculated based on information on the number of doctor's visits for routine asthma checkup, urgent treatment of worsening asthma symptoms, or an asthma episode or attack, as well as the number of asthma-related emergency room visits.

## **Statistical Analysis**

Analyses were performed in 2013 following previously used methods using SAS, version 9.3 (SAS Institute Inc., Cary NC) and SUDAAN, Release 10.0.1 (Research Triangle

Institute, Research Triangle Park NC). <sup>15,23</sup> We restricted analyses to adults aged 18–64 years with current asthma because of the age- and condition-specific recommendations for influenza vaccinations during 2006–2009. <sup>4,7–10</sup>

## Results

A total of 55,105 adults aged 18 years ever diagnosed with asthma participated in ACBS in 2006–2009; of these a total of 28,809 (representing an estimated annual average of 14.4 million) adults with current asthma aged 18–64 years were included in this analysis. The median response rates among the 38 states and District of Columbia providing data for this report ranged from 47.5% to 51.4% for BRFSS and 47.2% to 54.3% for ACBS.<sup>21,22</sup>

Of all adults aged 18–64 years with current asthma, an estimated annual average 42.7% received influenza vaccination during 2006–2009 (range: 25.8% for persons with no health insurance to 60.3% for those who stayed overnight in a hospital) (Table 1). Although coverage was higher among adults with WRA than those with non-WRA (48.5% vs 42.8%, respectively), the association between WRA status and vaccination coverage was not significant after adjusting for covariates (adjusted prevalence ratio=1.08; 95% CI=0.98, 1.20).

Influenza vaccination coverage and multivariate logistic regression results for influenza vaccination by WRA status are shown in Table 2. Influenza vaccination coverage among persons with non-WRA (an estimated 7.7 million) ranged from 26.1% among persons with no health insurance to 61.2% among those who stayed overnight in a hospital because of asthma in the past 12 months.

On multivariate analysis, among persons with non-WRA, vaccination coverage was significantly higher in subgroups similar to those for all adults with current asthma. Influenza vaccination coverage among persons with WRA (an estimated 1.3 million) ranged from 36.6% among non-Hispanic blacks to 58.6% among Hispanics and was significantly associated with age 50–64 years, lack of employment, and receiving urgent treatment for worsening asthma. Overall, vaccination coverage was significantly higher among asthmatics with a history of at least one physician contact in the previous year compared with those with no contact (Table 2).

## **Discussion**

In this population-based study, the estimated annual average influenza vaccination coverage during 2006–2009 in adults aged 18–64 years was 48.5% in those with WRA and 42.8% in those with non-WRA. These rates were higher than those of the general age-matched U.S. adult population during the 2006–2007 season (39.9%) but less than the Healthy People 2010 target of 60%. <sup>19,24</sup> These results are similar to other studies showing that vaccine uptake in adults is suboptimal. <sup>19,20,25–27</sup> The notable vaccination coverage difference among adults with WRA was the increased likelihood of vaccination among the unemployed. This may reflect the association between severity of WRA and job loss. <sup>28,29</sup>

Barriers to vaccination include lack of knowledge about these vaccines among adult patients and healthcare providers, the perception of feeling healthy, vaccine safety concerns, vaccination costs, lack of health insurance, and lack of financing mechanisms. <sup>25,30</sup> Low influenza vaccination coverage among employed adults and those with routine asthma checkups may indicate missed opportunities for vaccination.

Also, contrary to previous reports, <sup>27,31</sup> among all asthma patients with at least one physician visit, influenza vaccination coverage did not increase with increasing number of physician contacts. <sup>9</sup> No data were available in the ACBS to examine potential factors (e.g., vaccine availability, vaccination policies, public and clinician knowledge and practices, person's belief that they were in a high-risk group) that would explain why vaccination opportunities have been missed. <sup>8,30,32</sup> The use of electronic health records with clinical decision support and physician prompts may improve influenza vaccination rates. <sup>33</sup>

Additionally, influenza vaccination coverage may be increased by offering and improving vaccination in workplaces.<sup>34</sup> Blank et al.<sup>30</sup> reported that the most important motivating factors for receiving influenza vaccine in the U.S. were media advertising, physician's advice, and advice from family, friends, or relatives. The authors concluded that improvement in vaccine coverage rates can be achieved by accurate communication of health information, particularly by physicians. Similar results have been reported by others. <sup>32,35,36</sup>

Across all analyzed groups, the lowest influenza vaccination coverage was noted among persons without health insurance. In the coming years, access to medical care and preventive services, including influenza vaccination, is expected to improve owing to passage of the Patient Protection and Affordable Care Act of 2010.<sup>27,37</sup>

Information on asthma and influenza vaccination was not validated; thus, estimates may be subject to misclassification. However, previous studies have found self-report of adult influenza vaccination to be reliable compared with reviews of medical records. <sup>38,39</sup> This analysis used combined data years and influenza vaccination reported in the past 12 months rather than influenza season—specific coverage, which may produce different vaccination prevalence (http://cdc.gov/flu/fluvaxview/index.htm).

The cross-sectional design of BRFSS does not allow for examination of causal associations between adverse asthma outcomes and receiving influenza vaccination. For example, it is not clear whether influenza vaccination occurred before, during, or after unscheduled asthma treatment. Also, during 2006–2009, persons who resided in households that lacked a landline telephone and those who only used cellular telephones were not interviewed, likely resulting in vaccination coverage overestimatation. Finally, estimates are limited to the 38 states and District of Columbia and do not represent the entire U.S. population.

## **Conclusions**

More effective influenza vaccination and communication strategies are needed to meet the updated Healthy People 2020 goal of increasing annual influenza vaccination coverage among adults aged 18 years to 70%. 41

# **Acknowledgments**

We thank the Behavioral Risk Factor Surveillance System state coordinators for their assistance in collecting the data used in this analysis. We thank Dr. Peng-jun Lu, National Center for Immunization and Respiratory Diseases, CDC, and Dr. Paul Garbe, National Center for Environmental Health, CDC, for their helpful comments.

## References

- Moorman JE, Akinbami LJ, Bailey CM. National surveillance of asthma: United States, 2001–2010.
   National Center for Health Statistics Vital Health Stat. 2012; 3(35):1–58.
- Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the U.S., 2009. N Engl J Med. 2009; 361(20):1935–44. [PubMed: 19815859]
- 3. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005; 165(3):274–80. [PubMed: 15710789]
- 4. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005; 54(RR-8):1–40. [PubMed: 16086456]
- Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000; 284(13):1655– 63. [PubMed: 11015795]
- Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clin Infect Dis. 2009; 48(3):292–8. [PubMed: 19115970]
- 7. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR–6): 1–54. [PubMed: 17625497]
- Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57(RR-7): 1–60. [PubMed: 18685555]
- Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009; 58(RR-8):1–52. [PubMed: 19644442]
- Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-10):1–42. [PubMed: 16874296]
- 11. National Heart, Lung, and Blood Institute, Expert panel report 3: guidelines for the diagnosis and management of asthma Full report 2007. Bethesda MD: National Heart, Lung, and Blood Institute, NIH; 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
- 12. Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College of Chest Physicians consensus statement. Chest. 2008; 134(3S):S1–S41.
- 13. Knoeller GE, Mazurek JM, Moorman JE. Health-related quality of life among adults with work-related asthma in the United States. Qual Life Res. 2013; 22(4):771–80. [PubMed: 22661107]
- 14. Knoeller GE, Mazurek JM, Moorman JE. Work-related asthma, financial barriers to asthma care, and adverse asthma outcomes: asthma call-back survey, 37 states and District of Columbia, 2006 to 2008. Med Care. 2011; 49(12):1097–104. [PubMed: 22002642]
- 15. Knoeller GE, Mazurek JM, Moorman JE. Asthma symptoms among adults with work-related asthma. J Asthma. 2013; 50(2):166–73. [PubMed: 23259750]
- 16. Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy. 2005; 35(7):954–9. [PubMed: 16008684]
- 17. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for

- clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180(1):59–99. [PubMed: 19535666]
- Ford ES, Williams SG, Mannino DM, Redd SC. Influenza vaccination coverage among adults with asthma: findings from the 2000 Behavioral Risk Factor Surveillance System. Am J Med. 2004; 116(8):555–8. [PubMed: 15063818]
- 19. Lu PJ, Euler GL, Callahan DB. Influenza vaccination among adults with asthma findings from the 2007 BRFSS survey. Am J Prev Med. 2009; 37(2):109–15. [PubMed: 19589448]
- 20. Lu PJ, Callahan DB, Ding H, Euler GL. Influenza A (H1N1) 2009 monovalent vaccination among adults with asthma, U.S., 2010. Am J Prev Med. 2011; 41(6):619–26. [PubMed: 22099240]
- 21. CDC. 2009 Behavioral Risk Factor Surveillance System, Summary Data Quality Report. www.cdc.gov/brfss/annual\_data/2009/2009\_Summary\_Data\_Quality\_Report.docx
- CDC. 2009 Behavioral Risk Factor Surveillance System, Asthma Call-Back Survey, summary data quality report. Atlanta GA: CDC; 2009. www.cdc.gov/brfss/acbs/2009/documentation/ SDQReportACBS\_09.pdf
- CDC. Behavioral Risk Factor Surveillance System: BRFSS Asthma CallBack Survey, 2006–2010
   ACBS history and analysis guidance. Atlanta GA: CDC; 2010. www.cdc.gov/brfss/acbs/history/ ACBS\_06\_10.pdf
- USDHHS. Archive—Healthy People. healthypeople.gov/2010/document/html/objectives/ 14-29.htm
- 25. CDC. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(2):1–64.
- 26. Takayama M, Wetmore CM, Mokdad AH. Characteristics associated with the uptake of influenza vaccination among adults in the U.S. Prev Med. 2012; 54(5):358–62. [PubMed: 22465670]
- Williams WW, Lu PJ, Lindley MC, Kennedy ED, Singleton JA. Influenza vaccination coverage among adults—National Health Interview Survey, United States, 2008–09 influenza season. MMWR Morb Mortal Wkly Rep. 2012; 61(1S):S65–S72.
- Le Moual N, Kauffmann F, Eisen EA, Kennedy SM. The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work. Am J Respir Crit Care Med. 2008; 177(1):4–10. [PubMed: 17872490]
- 29. White GE, Mazurek JM, Moorman JE. Work-related asthma and employment status—38 states and District of Columbia, 2006–2009. J Asthma. 2013; 50(9):954–9. [PubMed: 23889492]
- 30. Blank PR, Bonnelye G, Ducastel A, Szucs TD. Attitudes of the general public and general practitioners in five countries towards pandemic and seasonal influenza vaccines during season 2009/2010. PLoS One. 2012; 7(10):e45450. [PubMed: 23071519]
- 31. CDC. Influenza vaccination coverage among persons with asthma— U.S., 2005–06 influenza season. MMWR Morb Mortal Wkly Rep. 2008; 57(24):653–7. [PubMed: 18566564]
- 32. Galarce EM, Minsky S, Viswanath K. Socioeconomic status, demographics, beliefs and A(H1N1) vaccine uptake in the U.S. Vaccine. 2011; 29(32):5284–9. [PubMed: 21621577]
- 33. McAuliffe K, Peddecord KM, Wang W, et al. Influenza vaccination and its association with clinic use of evidence-based practices and individual patient characteristics, San Diego County, 2009. J Public Health Manag Pract. 2013; 19(2):178–86. [PubMed: 23358297]
- 34. Nowalk MP, Lin CJ, Toback SL, et al. Improving influenza vaccination rates in the workplace: a randomized trial. Am J Prev Med. 2010; 38(3):237–46. [PubMed: 20036102]
- 35. Maurer J, Uscher-Pines L, Harris KM. Perceived seriousness of seasonal and A(H1N1) influenzas, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter? Prev Med. 2010; 51(2):185–7. [PubMed: 20510270]
- 36. Maurer J, Harris KM. Contact and communication with healthcare providers regarding influenza vaccination during the 2009–2010 H1N1 pandemic. Prev Med. 2011; 52(6):459–64. [PubMed: 21457726]
- 37. Frieden TR. CDC. Use of selected clinical preventive services among adults —U.S 2007–2010. MMWR Morb Mortal Wkly Rep. 2012; 61(1S):S1–S2.
- 38. Mac Donald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med. 1999; 16(3):173–7. [PubMed: 10198654]

39. Nichol KL, Korn JE, Baum P. Estimation of outpatient risk characteristics and influenza vaccination status: validation of a self-administered questionnaire. Am J Prev Med. 1991; 7(4): 199–203. [PubMed: 1756055]

- 40. Hu SS, Balluz L, Battaglia MP, Frankel MR. Improving public health surveillance using a dual-frame survey of landline and cell phone numbers. Am J Epidemiol. 2011; 173(6):703–11. [PubMed: 21343246]
- 41. USDHHS. Immunization and Infectious Diseases—Healthy People. www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=23

 $\label{thm:condition} \textbf{Table 1}$  Characteristics of adults aged 18–64 years with current asthma and influenza vaccination  $coverage^a$ 

			Influenza vacci	nation coverage
Characteristics	n in sample $b$	Population % <sup>c</sup> (95% CI)	% <sup>d</sup> (95% CI)	PR <sup>e</sup> (95% CI)
Age group (years)				
18–49	13,956	70.1 (69.0, 71.1)	36.3 (34.5, 38.2)	1.00 (ref)
50–64	14,853	29.9 (28.9, 31.0)	57.5 (55.9, 59.1)	1.52 (1.43, 1.61)
Gender				
Male	7,525	37.9 (36.4, 39.4)	38.9 (36.3, 41.5)	1.00 ref
Female	21,284	62.1 (60.6, 63.6)	45.0 (43.5, 46.5)	1.13 (1.05, 1.21)
Race/ethnicity				
White, non-Hispanic	23,191	74.1 (72.8, 75.5)	44.4 (42.9, 46.0)	1.00 ref
Black, non-Hispanic	1,721	9.0 (8.2, 9.8)	34.5 (30.3, 38.7)	0.81 (0.71, 0.92)
Hispanic	1,446	9.6 (8.6, 10.6)	37.0 (31.6, 42.4)	0.94 (0.82, 1.09)
Other, non-Hispanic	2,271	7.3 (6.5, 8.1)	42.1 (36.5, 47.8)	1.01 (0.89, 1.15)
Education level				
High school	9,462	34.3 (32.9, 35.8)	39.7 (37.0, 42.4)	0.98 (0.91, 1.06)
>High school	19,331	65.7 (64.2, 67.5)	44.3 (42.7, 45.9)	1.00 ref
Household income (\$)				
<50,000	14,911	51.0 (49.5, 52.4)	38.4 (36.4, 40.4)	1.00 ref
50,000	11,564	49.0 (47.6, 50.5)	47.0 (45.0, 48.9)	1.13 (1.06, 1.21)
Health insurance				
Yes	25,327	85.9 (84.8, 87.1)	45.5 (44.0, 46.9)	1.00 ref
No	3,383	14.1 (12.9, 15.2)	25.8 (21.6, 30.0)	0.64 (0.54, 0.75)
Employment status <sup>f</sup>				
Employed	17,538	64.0 (62.6, 65.4)	41.3 (39.6, 43.0)	1.00 ref
Not employed	11,271	36.0 (34.6, 37.4)	45.3 (42.9, 47.7)	1.04 (0.96, 1.12)
Work-related asthma				
Work-related asthma	3,003	8.9 (8.3, 9.6)	48.5 (44.7, 52.4)	1.08 (0.98, 1.20)
Possible work-related asthma	11,421	36.9 (35.5, 38.2)	41.1 (39.0, 43.3)	0.98 (0.92, 1.05)
Non-work-related asthma	14,226	54.2 (52.8, 55.6)	42.8 (40.8, 44.8)	1.00 ref
Other chronic disease <sup>g</sup>				
Yes	6,170	15.3 (14.5, 16.1)	53.4 (50.7, 56.1)	1.16 (1.08, 1.24)
No	22,372	84.7 (83.9, 85.5)	40.8 (39.2, 42.3)	1.00 ref
Ability to see a doctor for asthr	na if needed <sup>f</sup>	·	·	
Yes	25,442	87.7 (86.7, 88.6)	44.6 (43.1, 46.0)	1.27 (1.12, 1.46
	· · · · · · · · · · · · · · · · · · ·			

			Influenza vacci	nation coverage
Characteristics	$n$ in sample $^b$	<b>Population %</b> <sup>c</sup> (95% CI)	% <sup>d</sup> (95% CI)	PR <sup>e</sup> (95% CI)
Yes	24,559	86.5 (85.5, 87.5)	42.9 (41.4, 44.4)	1.02 (0.92, 1.13)
No	3,965	13.5 (12.5, 14.5)	41.1 (37.4, 44.8)	1.00 ref
Physician contactsh				
None	11,567	42.5 (41.1, 43.9)	32.1 (30.2, 34.0)	1.00 ref
1	5,127	18.7 (17.5, 19.9)	49.8 (46.1, 53.5)	1.40 (1.27, 1.54)
2–3	5,434	18.7 (17.7, 19.7)	48.6 (45.7, 51.5)	1.40 (1.28, 1.52)
4–9	4,683	14.0 (13.1, 14.8)	52.4 (49.1, 55.7)	1.42 (1.30, 1.55)
10	1,898	6.1 (5.5, 6.7)	50.7 (45.7, 55.6)	1.48 (1.30, 1.69)
Asthma control				
Well controlled	13,817	50.6 (49.2, 52.1)	40.3 (38.4, 42.3)	1.00 ref
Not well controlled	7,438	27.1 (25.8, 28.4)	43.1 (40.3, 45.9)	1.10 (1.02, 1.19)
Very poorly controlled	7,543	22.2 (21.2, 23.3)	47.7 (45.1, 50.3)	1.16 (1.07, 1.25)
${\bf Adverse\ asthma\ outcomes}^f$				
Asthma attack				
Yes	15,653	53.0 (51.6, 54.5)	44.4 (42.5, 46.3)	1.08 (1.01, 1.15)
No	12,902	47.0 (45.5, 48.4)	40.7 (38.6, 42.8)	1.00 ref
Urgent treatment for worser	ning asthma			
Yes	7,251	23.4 (22.4, 24.5)	49.2 (46.6, 51.7)	1.18 (1.10, 1.26)
No	21,155	76.6 (75.5, 77.6)	40.3 (38.7, 41.9)	1.00 ref
Asthma-related emergency	room visit			
Yes	3,578	12.2 (11.3, 13.1)	45.0 (41.1, 48.9)	1.08 (0.97, 1.20)
No	25,083	87.8 (86.9, 88.7)	42.1 (40.7, 43.6)	1.00 ref
Overnight stay in hospital b	ecause of asthma			
Yes	1,120	3.2 (2.7, 3.7)	60.3 (53.5, 67.0)	1.28 (1.11, 1.45)
No	27,531	96.8 (96.3, 97.3)	41.9 (40.5, 43.3)	1.00 ref
Total	28,809		42.7 (41.3, 44.1)	

Note: Boldface indicates significance.

<sup>&</sup>lt;sup>a</sup>Data were collected in 38 states (Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin) and the District of Columbia during 2006–2009.

 $<sup>^{</sup>b}$ Unweighted sample size (the numbers may not add up to the total because of missing values)

<sup>&</sup>lt;sup>c</sup>Distribution presented as weighted average annual estimate

 $<sup>\</sup>ensuremath{^{d}}\xspace^{\ensuremath{Proportion}}$  presented as weighted average annual estimate

 $<sup>^{</sup>e}$ Adjusted for age, gender, race/ethnicity, annual household income, health insurance, and chronic disease. For each model, the outcome variable was influenza vaccination.

f<sub>In the past 12 months</sub>

PR, prevalence ratio

 $<sup>^</sup>g\mathrm{Diabetes}$  or cardiovascular disease

h Includes doctor's visits for routine asthma checkup, doctor's visits for urgent treatment of worsening asthma symptoms or an asthma episode or attack, and emergency room visits because of asthma in the past 12 months

**Author Manuscript** 

**Author Manuscript** 

Influenza vaccination coverage and multivariate logistic regression results for influenza vaccination by work-related asthma status<sup>a</sup> Table 2

		Work-related asthma	ma	Poss	Possible work-related asthma	asthma	Ž	Non-work-related asthma	thma
		Influenza vacci	uenza vaccination coverage		Influenza vacci	Influenza vaccination coverage		Influenza vacci	Influenza vaccination coverage
Characteristics	$n$ in sample $^{b}$	% (95% CI) <sup>c</sup>	PR <sup>c</sup> d (95% CI)	n in sample $b$	%c (95% CI)	$PR^{c,d}$ (95% CI)	n in sample $b$	%c (95% CI)	PR <sup>c,d</sup> (95% CI)
Age group (years)									
18–49	1,206	42.0 (36.3, 47.6)	1.00 (ref)	5,351	33.9 (31.0, 36.7)	1.00 (ref)	7,340	37.1 (34.6, 39.7)	1.00 (ref)
50–64	1,797	57.2 (52.3, 62.1)	1.36 (1.15, 1.61)	6,070	56.5 (54.1, 59.0)	1.48 (1.36, 1.62)	6,886	58.5 (60.3, 65.4)	1.56 (1.44, 1.69)
Gender									
Male	936	46.9 (40.4, 53.3)	1.00 ref	3,020	37.7 (33.5, 42.0)	1.00 ref	3,522	38.3 (34.5, 42.0)	1.00 ref
Female	2,067	49.5 (44.7, 54.3)	1.08 (0.91, 1.29)	8,401	43.4 (41.1, 45.6)	1.05 (0.93, 1.17)	10,704	45.4 (43.1, 47.6)	1.19 (1.07, 1.32)
Race/ethnicity									
White, non-Hispanic	2,318	48.4 (44.0, 52.8)	1.00 ref	9,051	44.4 (42.0, 46.7)	1.00 ref	11,707	43.9 (41.6, 46.1)	1.00 ref
Black, non-Hispanic	224	36.6 (25.0, 48.3)	0.77 (0.55, 1.08)	733	35.6 (29.0, 42.2)	0.84 (0.68, 1.02)	745	33.2 (27.0, 39.4)	0.80 (0.65, 0.97)
Hispanic	155	58.6 (45.1, 72.2)	1.22 (0.92, 1.62)	582	28.4 (21.5, 35.3)	0.77 (0.62, 0.96)	869	38.9 (31.0, 46.9)	1.00 (0.81, 1.24)
Other, non-Hispanic	290	52.9 (40.7, 65.2)	1.01 (0.78, 1.32)	626	35.8 (26.4, 45.1)	0.89 (0.70, 1.12)	686	45.3 (38.0, 52.5)	1.12 (0.94, 1.34)
Education level									
High school	1,084	42.7 (36.3, 49.1)	0.87 (0.72, 1.05)	3,930	36.3 (32.5, 40.2)	0.94 (0.85, 1.05)	4,384	41.6 (37.5, 45.7)	1.03 (0.93, 1.15)
>High school	1,919	52.4 (47.6, 57.2)	1.00 ref	7,486	44.0 (41.4, 46.6)	1.00 ref	9,831	43.3 (41.0, 45.5)	1.00 ref
Household income (\$)									
<50,000	1,851	46.7 (41.5, 51.9)	1.00 ref	6,536	36.1 (33.1, 39.1)	1.00 ref	6,441	38.5 (35.6, 41.4)	1.00 ref
50,000	946	51.8 (45.4, 58.3)	1.07 (0.91, 1.27)	4,008	48.6 (45.4, 51.7)	1.19 (1.07, 1.32)	6,559	45.4 (42.8, 48.0)	1.11 (1.01, 1.23)
Health insurance									
Yes	2,558	50.9 (46.8, 55.0)	1.00 ref	9,817	45.1 (42.8, 47.3)	1.00 ref	12,818	44.8 (42.7, 46.9)	1.00 ref
No	437	37.0 (26.4, 47.6)	0.72 (0.52, 1.00)	1,565	23.1 (16.9, 29.4)	0.58 (0.45, 0.76)	1,356	26.1 (19.4, 32.7)	0.67 (0.52, 0.85)
Employment status $^{ ho}$									
Employed	1,635	43.1 (38.1, 48.1)	1.00 ref	966'9	38.2 (35.5, 40.8)	1.00 ref	8,811	43.2 (40.8, 45.6)	1.00 ref
Not employed	1,368	55.6 (49.9, 61.3)	1.44 (1.20, 1.73)	4,426	47.2 (43.7, 50.7)	1.08 (0.95, 1.22)	5,415	42.0 (38.5, 45.6)	0.93 (0.83, 1.04)
Other chronic disease $^f$									

		Work-related asthma	ma	Pos	Possible work-related asthma	asthma	Ž	Non-work-related asthma	thma
		Influenza vacci	Influenza vaccination coverage		Influenza vacci	Influenza vaccination coverage		Influenza vacci	Influenza vaccination coverage
Characteristics	$n$ in sample $^{b}$	% (95% CI) <sup>c</sup>	PR <sup>c,d</sup> (95% CI)	$\it n$ in sample $\it b$	%c (95% CI)	PR <sup>c,d</sup> (95% CI)	$\it n$ in sample $\it b$	%c (95% CI)	PR <sup>c,d</sup> (95% CI)
Yes	848	51.8 (44.4, 59.2)	1.07 (0.87, 1.31)	2,631	46.3 (52.5, 60.1)	1.25 (1.13, 1.39)	2,647	51.5 (47.2, 55.8)	1.10 (0.99, 1.23)
No	2,125	47.3 (42.7, 51.9)	1.00 ref	8,657	38.2 (35.8, 40.7)	1.00 ref	11,479	41.4 (39.2, 43.7)	1.00 ref
Ability to see a doctor for asthma if needed $^{arepsilon}$	asthma if need	led <sup>e</sup>							
Yes	2,433	50.8 (46.5, 55.1)	1.08 (0.84, 1.40)	9,746	44.4 (42.0, 46.8)	1.28 (1.07, 1.55)	13,178	43.7 (41.6, 45.8)	1.37 (1.09, 1.71)
No	563	40.9 (31.6, 50.2)	1.00 ref	1,640	26.0 (21.6, 30.4)	1.00 ref	666	30.8 (24.7, 36.9)	1.00 ref
Routine checkup for asthma $^e$	na <sup>e</sup>								
Yes	2,636	49.1 (45.1, 53.2)	1.18 (0.87, 1.60)	9,745	41.6 (39.3, 43.9)	1.07 (0.88, 1.31)	12,050	42.7 (40.5, 44.8)	0.97 (0.86, 1.09)
No	332	42.7 (29.4, 55.9)	1.00 ref	1,579	37.7 (31.6, 43.8)	1.00 ref	2,043	43.2 (38.3, 48.2)	1.00 ref
Physician contacts $^g$									
None	952	39.5 (32.5, 46.5)	1.00 ref	4,330	27.9 (25.1, 30.8)	1.00 ref	6,240	33.7 (31.1, 36.4)	1.00 ref
1	410	50.0 (39.8, 60.2)	1.32 (1.02, 1.71)	1,924	50.1 (44.6, 55.6)	1.58 (1.32, 1.90)	2,778	49.7 (44.5, 54.9)	1.33 (1.19, 1.49)
2–3	574	53.1 (44.0, 62.2)	1.39 (1.09, 1.78)	2,256	46.3 (41.9, 50.7)	1.45 (1.27, 1.66)	2,579	49.8 (45.6, 54.0)	1.38 (1.22, 1.56)
4–9	704	56.3 (49.0, 63.5)	1.48 (1.17, 1.87)	2,028	53.0 (47.7, 58.3)	1.61 (1.40, 1.85)	1,908	50.3 (45.3, 55.3)	1.29 (1.12, 1.48)
10	353	50.0 (38.5, 61.4)	1.33 (1.00, 1.77)	854	53.5 (46.9, 60.1)	1.71 (1.44, 2.03)	671	48.8 (39.7, 57.8)	1.43 (1.14, 1.81)
Asthma control									
Well controlled	1,137	46.8 (40.6, 53.1)	1.00 ref	4,848	37.2 (34.0, 40.4)	1.00 ref	7,766	41.1 (38.5, 43.8)	1.00 ref
Not well controlled	763	45.4 (38.1, 52.7)	1.05 (0.85, 1.30)	3,167	43.5 (39.3, 47.8)	1.15 (1.01, 1.31)	3462	42.6 (38.5, 46.7)	1.08 (0.97, 1.21)
Very poorly controlled	1,102	52.9 (46.4, 59.3)	1.20 (0.99, 1.46)	3,403	45.2 (41.4, 48.9)	1.16 (1.03, 1.30)	2996	48.6 (44.4, 52.7)	1.15 (1.01, 1.30)
Adverse asthma outcomes $\boldsymbol{^d}$	p								
Asthma attack									
Yes	1,983	49.8 (45.1, 54.5)	1.05 (0.88, 1.26)	6,865	43.5 (40.7, 46.3)	1.13 (1.01, 1.27)	6,721	43.7 (40.8, 46.7)	1.06 (0.97, 1.16)
No	666	45.9 (39.1, 52.7)	1.00 ref	4,458	37.7 (34.2, 41.2)	1.00 ref	7,387	41.7 (39.0, 44.5)	1.00 ref
Urgent treatment for worsening asthma	ening asthma								
Yes	1,054	55.0 (48.6, 61.4)	1.25 (1.06, 1.48)	3,202	49.4 (45.7, 53.1)	1.23 (1.12, 1.36)	2,929	47.3 (43.2, 51.3)	1.11 (1.00, 1.23)
No	1,905	45.4 (40.6, 50.3)	1.00 ref	8,046	37.7 (35.1, 40.4)	1.00 ref	11,127	41.2 (38.9, 43.5)	1.00 ref
Asthma-related emergency room visit	y room visit								

**Author Manuscript** 

**Author Manuscript** 

$\frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{\% (95\% \text{ CI})^c} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{\% (95\% \text{ CI})} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{\% (95\% \text{ CI})} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{\% (95\% \text{ CI})} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{\% (95\% \text{ CI})} \frac{\text{Influenza vaccination coverage}}{n \text{ in sample}^b} \frac{\text{Influenza vaccination coverage}}{n $					ř		
$^{2}p$ % (95% CI) $^{c}$	nation coverage		Influenza vacci	Influenza vaccination coverage		Influenza vacci	Influenza vaccination coverage
	PR <sup>c,d</sup> (95% CI)	n in sample $b$	%c (95% CI)	PR <sup>c,d</sup> (95% CI)	n in sample $b$	%c (95% CI)	PR <sup>c,d</sup> (95% CI)
55 49.9 (41.5, 58.3)	1.09 (0.91, 1.32)	1,627	47.2 (41.1, 53.4)	1.19 (1.01, 1.40)	1,376	41.1 (35.4, 46.9)	1.00 (0.84, 1.14)
38 48.5 (44.2, 52.9)	1.00 ref	9,751	39.9 (37.6, 42.1)	1.00 ref	12,786	42.6 (40.5, 44.7)	1.00 ref
Overnight stay in hospital because of asthma							
2 57.0 (42.0, 72.0)	1.15 (0.81, 1.63)	489	60.7 (50.1, 71.4)	1.30 (1.11, 1.53)	408	61.2 (50.7, 71.6)	1.29 (1.03, 1.61)
2,775 48.2 (44.2, 52.2)	1.00 ref	10,880	40.2 (38.0, 42.3)	1.00 ref	13,749	42.1 (40.0, 44.1)	1.00 ref
\$1\$1\$141b1	\$ 49.9 (41.5, 58.3) \$ 48.5 (44.2, 52.9)  sthma \$ 57.0 (42.0, 72.0)  \$ 48.2 (44.2, 52.2)	.9 (41.5, 58.3) 1.05 .5 (44.2, 52.9) .0 (42.0, 72.0) 1.15 .2 (44.2, 52.2)	.9 (41.5, 58.3) 1.09 (0.91, 1.32) .5 (44.2, 52.9) 1.00 ref .0 (42.0, 72.0) 1.15 (0.81, 1.63) .2 (44.2, 52.2) 1.00 ref	.9 (41.5, 58.3) 1.09 (0.91, 1.32) .5 (44.2, 52.9) 1.00 ref .0 (42.0, 72.0) 1.15 (0.81, 1.63) .2 (44.2, 52.2) 1.00 ref	.9 (41.5, 58.3) 1.09 (0.91, 1.32) 1,627 47.2 (41.1, 53.4) 1.15 .5 (44.2, 52.9) 1.00 ref 9,751 39.9 (37.6, 42.1) .0 (42.0, 72.0) 1.15 (0.81, 1.63) 489 60.7 (50.1, 71.4) 1.34 .2 (44.2, 52.2) 1.00 ref 10,880 40.2 (38.0, 42.3)	.9 (41.5, 58.3)       1.09 (0.91, 1.32)       1,627       47.2 (41.1, 53.4)       1.19 (1.01, 1.40)         .5 (44.2, 52.9)       1.00 ref       9,751       39.9 (37.6, 42.1)       1.00 ref       1         .0 (42.0, 72.0)       1.15 (0.81, 1.63)       489       60.7 (50.1, 71.4)       1.30 (1.11, 1.53)       1         .2 (44.2, 52.2)       1.00 ref       10,880       40.2 (38.0, 42.3)       1.00 ref       1	.9 (41.5, 58.3) 1.09 (0.91, 1.32) .5 (44.2, 52.9) 1.00 ref .0 (42.0, 72.0) 1.15 (0.81, 1.63) .2 (44.2, 52.2) 1.00 ref

Note: Boldface indicates significance.

<sup>a</sup>Data were collected in 38 states (Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin) and the District of Columbia during 2006-2009.

 $^{b}$ Unweighted sample size (the numbers may not add up to the total because of missing values)

 $^{\mathcal{C}}$  Proportion presented as weighted average annual estimate

dAdjusted for age, gender, race/ethnicity, annual household income, health insurance, and other chronic disease. For each model, the outcome variable was influenza vaccination.

eIn the past 12 months

 $f_{\mbox{Diabetes}}$  or cardiovascular disease

<sup>9</sup>Includes doctor's visits for routine checkup for asthma, doctor's visits for urgent treatment of worsening asthma symptoms or an asthma episode or attack, and emergency room visits because of asthma in the past 12 months

PR, prevalence ratio